Humanized Mouse Vaccines

Identify polyfunctional differences within the development of combination cancer vaccines1

Leverage the power of polyfunctional immune cell analysis to accelerate vaccine development.

Download application highlight

Research Area

Development Stage

Discovery

Goal

Identify differences in combination vaccine structures resulting from tumor vaccine activation

How our Award-Winning IsoLight Single-Cell System is Making a Difference

polyfunctional cell

Solution

PSI revealed differences for more accurate evaluation of tumor vaccine efficacy in a preclinical setting

polyfunctional cell

Finding

Nanoparticle vaccine containing tumor antigens can efficiently activate CD8+ T cells and induce polyfunctional CD8+ T cells that are associated with antitumor activity

follow our data

Follow Our Data

See the latest published data in Vaccines and Immunology Research

Single-Cell CD8+ polyfunctionality and PSI are upregulated in NP-vaccinated mouse group relative to Naïve controls. A robust upregulation of polyfunctional (secreting multiple cytokines) human CD8+ T cells in HIS mice immunized with NP/Antigen/Ab was observed, compared to other groups of HIS mice.

We observed a statistically significant difference between the NP/Antigen/Ab group and both the Naïve and Antigen groups. The enhanced PSI was predominated by effector proteins.

Download application highlight
CD8 PSI

Solution

Detect Critical Differences

Antigen specific CD8+ T cell detection by tetramer. Splenocytes were isolated from immunized and naïve HIS mice and incubated with antigen peptide-loaded HLA-A*0201 tetramer.

Cell were stained with the following antibodies to human CD45, mouse CD45, human CD3, human CD4, human CD8 and human CD19. The percentage of Melan-A specific human CD8+ T cells was analyzed by Flowjo software.1

Percentage of Antigen Specific Human CD8 T Cells

Request a Seminar

Request a Seminar
Discover IsoLight